Abstract #1684

Distinguishing Sensitive and Resistant Early Therapy Response of Pancreatic Tumor Xenografts Using 13C-MRS of Hyperpolarized Pyruvate

Prasanta Dutta¹, G V. Martinez¹, N V. Rajeshkumar², A Le², A Maitra², C V. Dang², R A. Gatenby¹, R J. Gillies¹

¹Imaging, Moffitt Cancer Center & Research Institute, Tampa, FL, United States; ²School of Medicine, Johns Hopkins University, Baltimore, MD, United States

In this work, we have evaluated the efficacy of a small molecule drug (a potent LDH-A inhibitor,FX11) treatment to human pancreatic xenograft tumors via assessing the metabolic conversion of lactate from pyruvate using 13C magnetic resonance spectroscopy. Measurement of hyperpolarized 13C label flux between pyruvate and lactate is used to detect early response to therapy before differences in tumor volume were observed.